Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents A Cost-Effectiveness Analysis

被引:76
作者
Finckh, Axel
Bansback, Nick
Marra, Carlo A.
Anis, Aslam H.
Michaud, Kaleb
Lubin, Stanley
White, Marc
Sizto, Sonia
Liang, Matthew H.
机构
[1] Univ Geneva, Geneva, Switzerland
[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[3] Univ Nebraska Med Ctr, Omaha, NE USA
[4] Natl Data Bank Rheumat Dis, Wichita, KS USA
[5] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA
关键词
ONSET UNDIFFERENTIATED ARTHRITIS; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; METHOTREXATE TREATMENT; TREATMENT STRATEGIES; RADIOGRAPHIC DAMAGE; COMBINATION THERAPY; PLUS METHOTREXATE; PREDICTION RULE; CLINICAL-TRIALS;
D O I
10.7326/0003-4819-151-9-200911030-00006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Long-term control or remission of rheumatoid arthritis (RA) may be possible with very early treatment. However, no optimal first therapeutic strategy has been determined. Objective: To assess the potential cost-effectiveness of major therapeutic strategies for very early RA. Design: Decision analytic model with probabilistic sensitivity analyses. Data Sources: Published data, the National Data Bank for Rheumatic Diseases, and actual 2007 hospital costs. Target Population: U.S. adults with very early RA (symptom duration <= 3 months). Time Horizon: Lifetime. Perspective: Health care provider and societal. Intervention: 3 management strategies were compared: a symptomatic or "pyramid" strategy with initial nonsteroidal anti-inflammatory drugs, patient education, pain management, and low-dose glucocorticoids, and disease-modifying antirheumatic drugs (DMARDs) at 1 year for nonresponders; early DMARD therapy with methotrexate; and early therapy with biologics and methotrexate. Outcome Measures: Cost per quality-adjusted life-year (QALY) gained. Results of Base-Case Analysis: By reducing the progression of joint erosions and subsequent functional disability, both early inter-vention strategies increase quality-adjusted life more than the pyramid strategy and save long-term costs. When the cost of very early intervention is factored in, the cost-effectiveness ratio of the early DMARD strategy is $4849 per QALY (95% CI, $0 to $16 354 per QALY) compared with the pyramid strategy, whereas the benefits gained through the early biologic strategy come at a substantial incremental cost. The early DMARD strategy maximizes the effectiveness of early DMARDs and reserves the use of biologics for patients with more treatment-resistant disease of longer duration, for which the incremental benefit of biologics is greater. Results of Sensitivity Analysis: The early biologic strategy becomes more cost-effective if drug prices are reduced, risk for death is permanently lowered through biologic therapy, patients experience drug-free remission, responders can be selected before therapy initiation, or effective alternative antirheumatic agents are available for patients for whom several biologics have failed. Limitations: Data on the long-term effect of very early therapeutic interventions on the natural progression in disability and joint erosions are limited. The study considered only tumor necrosis factor inhibitors and not the newer biologics. Conclusion: According to the most objective measures of RA progression, very early intervention with conventional DMARDs is cost-effective. The cost-effectiveness of very early intervention with biologics remains uncertain.
引用
收藏
页码:612 / W198
页数:11
相关论文
共 63 条
[1]   Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years [J].
Aletaha, D ;
Eberl, G ;
Nell, VPK ;
Machold, KP ;
Smolen, JS .
ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (07) :630-634
[2]   Measuring function in rheumatoid arthritis - Identifying reversible and irreversible components [J].
Aletaha, Daniel ;
Smolen, Josef ;
Ward, Michael M. .
ARTHRITIS AND RHEUMATISM, 2006, 54 (09) :2784-2792
[3]  
Anderson JJ, 2000, ARTHRITIS RHEUM, V43, P22, DOI 10.1002/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO
[4]  
2-9
[5]  
[Anonymous], 1996, Cost-effectiveness in health and medicine
[6]  
Arias E., 2004, National vital statistics reports: United States life tables, 2002
[7]   THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[8]  
Barton Pelham, 2004, J Health Serv Res Policy, V9, P110, DOI 10.1258/135581904322987535
[9]   A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [J].
Bathon, JM ;
Martin, RW ;
Fleischmann, RM ;
Tesser, JR ;
Schiff, MH ;
Keystone, EC ;
Genovese, MC ;
Wasko, MC ;
Moreland, LW ;
Weaver, AL ;
Markenson, J ;
Finck, BK .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1586-1593
[10]   The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].
Breedveld, FC ;
Weisman, MH ;
Kavanaugh, AF ;
Cohen, SB ;
Pavelka, K ;
van Vollenhoven, R ;
Sharp, J ;
Perez, JL ;
Spencer-Green, GT .
ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37